AMDA (9-Aminometil-9,10-dihidroantracen) je organsko jedinjenje koji deluje kao potentan i selektivan antagonist za 5-HT2Areceptor.[5] On je korišten u studijama kojima je utvrđivan oblik 5-HT2A proteina,[6] i kao osnova za razvoj velike familije derivata sa povećanom potentnošću i selektivnošću.[7][8][9][10][11]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Westkaemper, RB; Runyon, SP; Bondarev, ML; Savage, JE; Roth, BL; Glennon, RA (1999). „9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist”. European Journal of Pharmacology380 (1): R5–7. DOI:10.1016/S0014-2999(99)00525-7. PMID10513561.
↑Runyon, SP; Peddi, S; Savage, JE; Roth, BL; Glennon, RA; Westkaemper, RB (2002). „Geometry-affinity relationships of the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene”. Journal of Medical Chemistry45 (8): 1656–64. DOI:10.1021/jm010354g. PMID11931619.